NASDAQ NMS - GLOBAL MARKET · BDTX
+0.52% · +$0.0100 · Vol 599.9K
Market closed · last close 4:00 PM ET · price as of 17:48:53 ET
Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc

Biotechnology
$1.93
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
BDTX
Black Diamond Therapeutics Inc
Fri Aug 7 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Fri Aug 7 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is BDTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BDTX catalysts
About Black Diamond Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
21
Country
US

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.94
Day high
$1.99
Day low
$1.91
Previous close
$1.92
52W high
$4.87
-60.37% from high
52W low
$1.61
10% of range
Market cap
$112M
P/E
5.01×
EPS
$-0.6700
Beta
1.42
Shares out
57.5M
Volume
599.9K
0.47× rel vol
Avg volume
1.3M
VWAP
$1.94
Price history computed in-house
1W
+14.20%
1M
+1.05%
3M
-34.35%
1Y
-19.58%
YTD
-20.58%
SMA 50 $1.85 · above
SMA 200 $2.59 · below
52W position 10%

BDTX overview

Veridion Score
59
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around BDTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading BDTX Form 4 filings
Public disclosures

Congress activity in BDTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for BDTX in the cached public ledger.

Federal contracts

BDTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BDTX in this window.
Lobbying spend

BDTX lobbying filings, year to date.

Registered lobbying filings matched to Black Diamond Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BDTX in this window.
Loading news for BDTX
Analyst ratings
Sovereign unlock shows live analyst consensus for BDTX.
Options
Sovereign unlock shows live options positioning for BDTX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.